Dr Rishu Agarwal
Honorary (Senior Fellow)
Department of Clinical Pathology
28 Scholarly works
2 Projects
HIGHLIGHTS
2024
Journal article
Laboratory validation and clinical utility of next-generation sequencing-based IGH/TCR clonality testing for the monitoring of measurable residual disease in acute lymphoblastic leukaemia: real-world experience at Austin Pathology
DOI: 10.1016/j.pathol.2024.04.0122024
Journal article
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions
DOI: 10.1182/blood.20230233882023
Journal article
A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naive Mantle Cell Lymphoma (MCL): First Report of the Investigator-Initiated Australasian Leukaemia & Lymphoma Group NHL33 'Wamm' Trial
DOI: 10.1182/blood-2023-1784032021
Research grants (other domestic)
Circulating Tumour DNA and Genomic Markers of Poor Response to Ibrutinib-Venetoclax Combination Therapy in Chronic Lymphocytic Leukaemia
2019
Research Grant
Defining Resistance Mechanisms and Clonal Dynamics in Chronic Lymphocytic Leukaemia Treated With Novel Targeted Therapies
2019
Journal article
Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
DOI: 10.1038/s41591-018-0243-z2018
Journal article
Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma
DOI: 10.1056/NEJMoa1715519
RECENT SCHOLARLY WORKS
2023
Journal article
NGS-based clonality testing is a sensitive and complementary method for MRD monitoring in acute lymphoblastic leukaemia
DOI: 10.1016/j.pathol.2022.12.1242022
Journal article
Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre
DOI: 10.1111/imj.158512022
Journal article
Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement
DOI: 10.1016/j.pathol.2022.03.0022021
Conference Proceedings
IMMUNE PRIMING WITH NIVOLUMAB FOLLOWED BY NIVOLUMAB & RITUXIMAB IN 1ST LINE TREATMENT OF FOLLICULAR LYMPHOMA: THE PHASE 2 1ST FLOR STUDY
DOI: 10.1002/hon.81_28792021
Journal article
Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative
DOI: 10.1016/j.pathol.2020.08.0192021
Conference Proceedings
Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.
DOI: 10.1200/JCO.2021.39.15_suppl.75602021
Journal article
Design, implementation and clinical utility of next generation sequencing in myeloid malignancies: acute myeloid leukaemia and myelodysplastic syndrome
DOI: 10.1016/j.pathol.2021.01.005